» Articles » PMID: 34032027

Production of a Promising Biosynthetic Self-Assembled Nanoconjugate Vaccine Against Klebsiella Pneumoniae Serotype O2 in a General Escherichia Coli Host

Overview
Journal Adv Sci (Weinh)
Date 2021 May 25
PMID 34032027
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Klebsiella pneumoniae has emerged as a severe opportunistic pathogen with multiple drug resistances. Finding effective vaccines against this pathogen is urgent. Although O-polysaccharides (OPS) of K. pneumoniae are suitable antigens for the preparation of vaccines given their low levels of diversity, the low immunogenicity (especially serotype O2) limit their application. In this study, a general Escherichia coli host system is developed to produce a nanoscale conjugate vaccine against K. pneumoniae using the Nano-B5 self-assembly platform. The experimental data illustrate that this nanoconjugate vaccine can induce an efficient humoral immune response in draining lymph nodes (dLNs) and elicit high titers of the IgG antibody against bacterial lipopolysaccharide (LPS). The ideal prophylactic effects of these nanoconjugate vaccines are further demonstrated in mouse models of both systemic and pulmonary infection. These results demonstrate that OPS with low immunogenicity can be changed into an effective antigen, indicating that other haptens may be applicable to this strategy in the future. To the knowledge, this is the first study to produce biosynthetic nanoconjugate vaccines against K. pneumoniae in E. coli, and this strategy can be applied to the development of other vaccines against pathogenic bacteria.

Citing Articles

Semisynthetic Glycoconjugate Vaccine Lead against Serotype O2afg Induces Functional Antibodies and Reduces the Burden of Acute Pneumonia.

Shen D, Seco B, Teixeira Alves L, Yao L, Brautigam M, Opitz B J Am Chem Soc. 2024; 146(51):35356-35366.

PMID: 39666976 PMC: 11673581. DOI: 10.1021/jacs.4c13972.


Lipopolysaccharide as a Vaccine Target and the Role of Antibodies in Protection from Disease.

Miller J, Cross A, Tennant S, Baliban S Vaccines (Basel). 2024; 12(10).

PMID: 39460343 PMC: 11512408. DOI: 10.3390/vaccines12101177.


Production of Promising Heat-Labile Enterotoxin (LT) B Subunit-Based Self-Assembled Bioconjugate Nanovaccines against Infectious Diseases.

Li C, Li J, Sun P, Li T, Yan X, Ye J Vaccines (Basel). 2024; 12(4).

PMID: 38675730 PMC: 11054625. DOI: 10.3390/vaccines12040347.


Efficient Production of Self-Assembled Bioconjugate Nanovaccines against O2 Serotype in Engineered .

Zhang Y, Sun P, Li T, Li J, Ye J, Li X Nanomaterials (Basel). 2024; 14(8).

PMID: 38668222 PMC: 11054253. DOI: 10.3390/nano14080728.


Impact of Protein Nanoparticle Shape on the Immunogenicity of Antimicrobial Glycoconjugate Vaccines.

Dolce M, Proietti D, Principato S, Giusti F, Adamo G, Favaron S Int J Mol Sci. 2024; 25(7).

PMID: 38612547 PMC: 11011275. DOI: 10.3390/ijms25073736.


References
1.
Shu L, Lu Q, Sun R, Lin L, Sun Q, Hu J . Prevalence and phenotypic characterization of carbapenem-resistant strains recovered from sputum and fecal samples of ICU patients in Zhejiang Province, China. Infect Drug Resist. 2018; 12:11-18. PMC: 6302810. DOI: 10.2147/IDR.S175823. View

2.
Pan C, Sun P, Liu B, Liang H, Peng Z, Dong Y . Biosynthesis of Conjugate Vaccines Using an O-Linked Glycosylation System. mBio. 2016; 7(2):e00443-16. PMC: 4850263. DOI: 10.1128/mBio.00443-16. View

3.
MacCalman T, Phillips-Jones M, Harding S . Glycoconjugate vaccines: some observations on carrier and production methods. Biotechnol Genet Eng Rev. 2020; 35(2):93-125. DOI: 10.1080/02648725.2019.1703614. View

4.
Trautmann M, Cross A, Reich G, Held H, Podschun R, Marre R . Evaluation of a competitive ELISA method for the determination of Klebsiella O antigens. J Med Microbiol. 1996; 44(1):44-51. DOI: 10.1099/00222615-44-1-44. View

5.
Peng Z, Wu J, Wang K, Li X, Sun P, Zhang L . Production of a Promising Biosynthetic Self-Assembled Nanoconjugate Vaccine against Klebsiella Pneumoniae Serotype O2 in a General Escherichia Coli Host. Adv Sci (Weinh). 2021; 8(14):e2100549. PMC: 8292882. DOI: 10.1002/advs.202100549. View